Nippon Shinyaku secures US commercialization rights for AB2 Bio’s Tadekinig alfa

• Nippon Shinyaku exercised option rights under its January 2025 agreement with AB2 Bio to commercialize Tadekinig alfa in the U.S.
• Deal grants exclusive U.S. commercialization rights for monogenic IL-18 driven hyperinflammatory syndrome in patients with NLRC4 and XIAP mutations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nippon Shinyaku Co. Ltd. published the original content used to generate this news brief on July 30, 2026, and is solely responsible for the information contained therein.